BACKGROUND AND PURPOSE: The phenotype of IBMPFD [inclusion body myopathy with Paget's disease of the bone and frontotemporal dementia (FTD)] associated with valosin-containing protein (VCP) mutation is described in three families. METHODS: Probands were identified based on a pathological diagnosis of frontotemporal lobar degeneration with TDP-43-positive inclusions type IV. VCP sequencing was carried out. Clinical data on affected family members were reviewed. RESULTS: Ohio family: four subjects presented muscle weakness and wasting. (One subject had both neuropathic and myopathic findings and another subject showed only evidence of myopathy. The etiology of weakness could not be ascertained in the remaining two subjects.) Two individuals also showed Parkinsonism (with associated FTD in one of the two). The proband's brain displayed FTLD-TDP type IV and Braak stage five Parkinson's disease (PD). A VCP R191Q mutation was found. Pennsylvania family: 11 subjects developed IBMPFD. Parkinsonism was noted in two mutation carriers, whilst another subject presented with primary progressive aphasia (PPA). A novel VCP T262A mutation was found. Indiana family: three subjects developed IBMPFD. FTD was diagnosed in two individuals and suspected in the third one who also displayed muscle weakness. A VCP R159C mutation was found. CONCLUSIONS: We identified three families with IBMPFD associated with VCP mutations. Clinical and pathological PD was documented for the first time in members of two families. A novel T262A mutation was found. One individual had PPA: an uncommon presentation of IBMPFD.
BACKGROUND AND PURPOSE: The phenotype of IBMPFD [inclusion body myopathy with Paget's disease of the bone and frontotemporal dementia (FTD)] associated with valosin-containing protein (VCP) mutation is described in three families. METHODS: Probands were identified based on a pathological diagnosis of frontotemporal lobar degeneration with TDP-43-positive inclusions type IV. VCP sequencing was carried out. Clinical data on affected family members were reviewed. RESULTS: Ohio family: four subjects presented muscle weakness and wasting. (One subject had both neuropathic and myopathic findings and another subject showed only evidence of myopathy. The etiology of weakness could not be ascertained in the remaining two subjects.) Two individuals also showed Parkinsonism (with associated FTD in one of the two). The proband's brain displayed FTLD-TDP type IV and Braak stage five Parkinson's disease (PD). A VCP R191Q mutation was found. Pennsylvania family: 11 subjects developed IBMPFD. Parkinsonism was noted in two mutation carriers, whilst another subject presented with primary progressive aphasia (PPA). A novel VCPT262A mutation was found. Indiana family: three subjects developed IBMPFD. FTD was diagnosed in two individuals and suspected in the third one who also displayed muscle weakness. A VCP R159C mutation was found. CONCLUSIONS: We identified three families with IBMPFD associated with VCP mutations. Clinical and pathological PD was documented for the first time in members of two families. A novel T262A mutation was found. One individual had PPA: an uncommon presentation of IBMPFD.
Authors: Kishore R Kumar; Merrilee Needham; Kym Mina; Mark Davis; Janice Brewer; Christopher Staples; Karl Ng; Carolyn M Sue; Frank L Mastaglia Journal: Neuromuscul Disord Date: 2010-03-23 Impact factor: 4.296
Authors: Janel O Johnson; Jessica Mandrioli; Michael Benatar; Yevgeniya Abramzon; Vivianna M Van Deerlin; John Q Trojanowski; J Raphael Gibbs; Maura Brunetti; Susan Gronka; Joanne Wuu; Jinhui Ding; Leo McCluskey; Maria Martinez-Lage; Dana Falcone; Dena G Hernandez; Sampath Arepalli; Sean Chong; Jennifer C Schymick; Jeffrey Rothstein; Francesco Landi; Yong-Dong Wang; Andrea Calvo; Gabriele Mora; Mario Sabatelli; Maria Rosaria Monsurrò; Stefania Battistini; Fabrizio Salvi; Rossella Spataro; Patrizia Sola; Giuseppe Borghero; Giuliana Galassi; Sonja W Scholz; J Paul Taylor; Gabriella Restagno; Adriano Chiò; Bryan J Traynor Journal: Neuron Date: 2010-12-09 Impact factor: 17.173
Authors: J van der Zee; D Pirici; T Van Langenhove; S Engelborghs; R Vandenberghe; M Hoffmann; G Pusswald; M Van den Broeck; K Peeters; M Mattheijssens; J-J Martin; P P De Deyn; M Cruts; D Haubenberger; S Kumar-Singh; A Zimprich; C Van Broeckhoven Journal: Neurology Date: 2009-08-25 Impact factor: 9.910
Authors: Nigel J Cairns; Manuela Neumann; Eileen H Bigio; Ida E Holm; Dirk Troost; Kimmo J Hatanpaa; Chan Foong; Charles L White; Julie A Schneider; Hans A Kretzschmar; Deborah Carter; Lisa Taylor-Reinwald; Katherine Paulsmeyer; Jeffrey Strider; Michael Gitcho; Alison M Goate; John C Morris; Manjari Mishra; Linda K Kwong; Anna Stieber; Yan Xu; Mark S Forman; John Q Trojanowski; Virginia M-Y Lee; Ian R A Mackenzie Journal: Am J Pathol Date: 2007-07 Impact factor: 4.307
Authors: Jeong-Sun Ju; Rodrigo A Fuentealba; Sara E Miller; Erin Jackson; David Piwnica-Worms; Robert H Baloh; Conrad C Weihl Journal: J Cell Biol Date: 2009-12-14 Impact factor: 10.539
Authors: E Al-Obeidi; S Al-Tahan; A Surampalli; N Goyal; A K Wang; A Hermann; M Omizo; C Smith; T Mozaffar; V Kimonis Journal: Clin Genet Date: 2018-01 Impact factor: 4.438
Authors: Nam Chul Kim; Emilie Tresse; Regina-Maria Kolaitis; Amandine Molliex; Ruth E Thomas; Nael H Alami; Bo Wang; Aashish Joshi; Rebecca B Smith; Gillian P Ritson; Brett J Winborn; Jennifer Moore; Joo-Yong Lee; Tso-Pang Yao; Leo Pallanck; Mondira Kundu; J Paul Taylor Journal: Neuron Date: 2013-03-14 Impact factor: 17.173